Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023

Rhea-AI Summary

Heron Therapeutics, Inc. (Nasdaq: HRTX) will host a conference call and live webcast on March 23, 2023, at 4:30 p.m. ET to report its fourth quarter and full year 2022 financial results along with recent business highlights. Investors can access the call by dialing (646) 307-1963 or (800) 715-9871 internationally, using passcode 7469717. A webcast will also be available on the company's website, with an archive accessible for 60 days post-call. Heron focuses on developing innovative treatments addressing significant unmet patient needs, particularly in acute care and oncology.

Positive

• Upcoming conference call on March 23, 2023, to detail financial performance.
• Focus on addressing unmet patient needs with innovative treatments.

Negative

• None.

SAN DIEGO, March 10, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Thursday, March 23, 2023 at 4:30 p.m. ET to report fourth quarter and full year 2022 financial results and discuss recent business highlights.

The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally. Please provide the operator with the passcode 7469717 to join the conference call. The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

Forward-looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:
David Szekeres
Executive Vice President, Chief Operating Officer
Heron Therapeutics, Inc.
dszekeres@herontx.com
858-251-4447

View original content:https://www.prnewswire.com/news-releases/heron-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-thursday-march-23-2023-301769304.html

SOURCE Heron Therapeutics, Inc.

FAQ

When will Heron Therapeutics announce its fourth quarter and full year 2022 financial results?

Heron Therapeutics will announce its fourth quarter and full year 2022 financial results on March 23, 2023.

How can I listen to the Heron Therapeutics conference call?

The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally, using passcode 7469717.

Where can I find the webcast of the Heron Therapeutics conference call?

The webcast of the conference call will be available on Heron Therapeutics' Investor Relations section of their website.

What is the focus of Heron Therapeutics as a company?

Heron Therapeutics is focused on developing best-in-class treatments for acute care and oncology patients to address significant unmet needs.